North China Pharmaceutical and Subsidiaries Have Eight Drugs Tentatively Selected for the 12th National Centralized Drug Procurement

财中社··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

North China Pharmaceutical announced that the company and its subsidiaries Huamin Company and Nanfang Company have a total of eight drugs tentatively selected for the 12th National Centralized Drug Procurement organized by the state. The tentatively selected products include ciclosporin soft capsules and tacrolimus capsules, with a public notice period from July 31 to August 5, 2026. In the first quarter of 2026, North China Pharmaceutical achieved revenue of 2.153 billion yuan and net profit attributable to the parent company of 35.47 million yuan.

Impact on assets 2

Energy Transition & Power Demand▲
Others▲

Off-coverage companies 1

华民公司i
Private▲ PositiveDemandrelevance

Subsidiary Huamin Company has drugs tentatively selected, benefiting from procurement.